Pharmaceutical R&D efficiency - a fleeting imperative
R&D efficiency – though remaining quite difficult to measure in ‘productive’ terms – is fast becoming a key differentiating factor between pharmaceutical companies
Pharmaceuticals Majors
Consumer products, a great game between pharma majors
Glaxo Smith Kline, just a few days after withdrawing as a potential buyer of the consumer health division Pfizer intends to auction, bought out the minority stake held by Novartis in their consumer healthcare joint venture
Consumer health products, a cautious approach
Glaxo Smith Kline will not bid for the Pfizer over-the-counter consumer health products, leaving the company without declared candidate as Reckitt Benckiser had also withdrawn a few days earlier
Consumer health products loose shine for Big Pharma
With aging populations in developed markets and health-conscious consumers driving demand for self-medication worldwide, consumer health products are a growing and profitable market segment overlaping more and more often with food conglomerates
Pharmaceuticals, Medical Devices and Consumer Products - an evolving mix
Strategic choices underpinning the mix between drugs, medical devices and consumer products – and the changing overall profile - are in many ways indicative of the broad trends commanding the pharmaceutical industry